Supernus Pharmaceuticals (NASDAQ:SUPN) Announces Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) announced its quarterly earnings data on Monday. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.17, MarketWatch Earnings reports. The company had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $150.47 million. Supernus Pharmaceuticals had a net margin of 9.21% and a return on equity of 6.75%. The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.11 EPS. Supernus Pharmaceuticals updated its FY 2022 guidance to EPS.

SUPN stock opened at $26.37 on Tuesday. The company has a 50-day simple moving average of $30.64 and a 200 day simple moving average of $30.66. The company has a market capitalization of $1.41 billion, a P/E ratio of 26.91 and a beta of 1.12. The company has a quick ratio of 1.63, a current ratio of 1.91 and a debt-to-equity ratio of 0.46. Supernus Pharmaceuticals has a fifty-two week low of $23.15 and a fifty-two week high of $34.50.

Several research analysts have commented on SUPN shares. TheStreet lowered Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, April 18th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 4th. Finally, StockNews.com raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 18th.

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its stake in Supernus Pharmaceuticals by 24.2% during the fourth quarter. Barclays PLC now owns 77,598 shares of the specialty pharmaceutical company’s stock valued at $2,263,000 after buying an additional 15,098 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $2,196,000. California State Teachers Retirement System boosted its position in shares of Supernus Pharmaceuticals by 2.9% during the 4th quarter. California State Teachers Retirement System now owns 71,871 shares of the specialty pharmaceutical company’s stock valued at $2,096,000 after purchasing an additional 2,034 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $1,695,000. Finally, Credit Suisse AG raised its holdings in shares of Supernus Pharmaceuticals by 1.2% in the 4th quarter. Credit Suisse AG now owns 52,584 shares of the specialty pharmaceutical company’s stock worth $1,533,000 after purchasing an additional 644 shares in the last quarter.

About Supernus Pharmaceuticals (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Read More